1.
Leuk Lymphoma
; 65(6): 857-859, 2024 Jun.
Article
in English
| MEDLINE
| ID: mdl-38419349
Subject(s)
Ascites , Immunoglobulin M , Paraproteinemias , Polycythemia , Telangiectasis , Humans , Polycythemia/diagnosis , Polycythemia/etiology , Polycythemia/complications , Paraproteinemias/diagnosis , Paraproteinemias/complications , Immunoglobulin M/blood , Ascites/etiology , Ascites/diagnosis , Ascites/pathology , Telangiectasis/diagnosis , Telangiectasis/etiology , Telangiectasis/pathology , Male , Aged , Syndrome , Female , Middle Aged
2.
Clin Nucl Med
; 49(4): 327-329, 2024 Apr 01.
Article
in English
| MEDLINE
| ID: mdl-38350084
ABSTRACT
ABSTRACT: A 24-year-old man with classical Hodgkin lymphoma was lost to follow-up after metabolic complete remission (mCR). He presented 4 years later with B-symptoms and impaired clinical condition. Relapsed classical Hodgkin lymphoma was diagnosed. PET/CT revealed stage IVB with liver and spleen involvement. Two liver function-adjusted salvage attempts were ineffective. Pembrolizumab was instituted with gradual clinical improvement. PET was missed before treatment for a life-threatening condition and was performed on day +10 showing a near mCR. A mCR was confirmed before cycle 2, on day +21, underlining-for the first time in the literature-the possibility to achieve very early mCR with pembrolizumab.